Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

Overview of attention for article published in OncoTargets and therapy, March 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 18,864 followers.

Agree @subatomicdoc recent results suggest de-escalated #radonc dose for #prostatecancer https://t.co/QO2I0G3e5K https://t.co/TLwA73ISUD

Reply Repost Favourite

RT @DrTPShakespeare: Agree @subatomicdoc recent results suggest de-escalated #radonc dose for #prostatecancer https://t.co/V43nxWD3Z0 http…

Reply Repost Favourite

RT @DrTPShakespeare: Agree @subatomicdoc recent results suggest de-escalated #radonc dose for #prostatecancer https://t.co/V43nxWD3Z0 http…

Reply Repost Favourite

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoady ADT? https://t.co/tsNBmNQX6A

Reply Repost Favourite